



Ms. ANJALI RAWTHER MOHAMMED RAFFI

PID NO: 47417

Age: 29 Years Sex: Female

DOB: 28-Aug-1995



Reference: Dr. AISHA

Referred Client:

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5080102297

Collected on:

07-Aug-2025 09:30 PM

Registered on:

08-Aug-2025 12:42 PM

Reported on:

08-Aug-2025 03:09 PM

<u>Investigation</u>	Observed Value	Flag Un	<u>nit</u>	Biological Reference Int	terval <u>Method</u>
COMPLETE BLOOD COUNT (CBC)					
HEMOGLOBIN	13.5	g/o	dL	12 - 15.5	Photometric
RBC COUNT	4.5	10)^6/μL	3.9 - 5	Electrical Impedance
HEMATOCRIT	40.0	%		35 - 45	Calculation
MCV	88.3	fL		82 - 98	Calculation
мсн	29.9	pg	5	27 - 32	Calculation
мснс	33.9	g/d	dL	32 - 37	Calculation
* RDW	12.8	%		11.9 - 15.5	Calculation
* RDW-SD	38.90	fL			Calculation
MPV	9.3	fL		7.6 - 10.8	Calculation
PLATELET COUNT	265	10)^3/uL	150 - 450	Electrical Impedance
* NUCLEATED RBC (NRBC)	0.1	/10	00 WBC		VCS 360 Technology
* ABSOLUTE NRBC COUNT	0.01	10)^3/uL		Calculation
TOTAL & DIFFERENTIAL COUNT (DC)					
WBC COUNT	9.0	10)^3/μL	4 - 11	Electrical Impedance
NEUTROPHILS	60	%		40 - 75	VCS 360 Technology
LYMPHOCYTES	34	%		30 - 60	VCS 360 Technology
EOSINOPHILS	2	%		0 - 6	VCS 360 Technology
MONOCYTES	4	%		1 - 6	VCS 360 Technology
BASOPHILS	0	%		0 - 1	VCS 360 Technology
ABSOLUTE COUNT					
ABSOLUTE NEUTROPHIL COUNT	5.40	10)^3/uL	1.6 - 8.25	Calculation
ABSOLUTE LYMPHOCYTE COUNT	3.06	10)^3/uL	1.2 - 6.6	Calculation
ABSOLUTE MONOCYTE COUNT	0.36	10)^3/uL	0.04 - 0.66	Calculation
ABSOLUTE EOSINOPHIL COUNT	0.18	10)^3/uL	0 - 0.66	Calculation
ABSOLUTE BASOPHIL COUNT	0	10)^3/uL	0 - 0.11	Calculation

Sample Type: EDTA Whole Blood

Cyona V. Shah

DR. ADLEY MARK FERNANDES DR. VYOMA SHAH M.D (Pathology) M.D (Pathology) **Pathologist Clinical Pathologist**

This is an Electronically Authenticated Report.

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (*). Test marked with # is performed in an accredited referral laboratory.







ANJUMOL VADAKKINATHU

Laboratory Technologist



Tel: 971 4 398 8567 www.biosytech.com

Ms. ANJALI RAWTHER MOHAMMED RAFFI

PID NO: 47417

Age: 29 Years Sex: Female

DOB: 28-Aug-1995



Reference: Dr. AISHA

Referred Client:

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5080102297

Collected on:

07-Aug-2025 09:30 PM

Registered on:

08-Aug-2025 12:42 PM

Reported on:

08-Aug-2025 03:17 PM

Investigation **Observed Value** Flag Unit **Biological Reference Interval**

* C-REACTIVE PROTEIN (CRP)

(Serum, Particle-enhanced immunoturbidimetric assay)

< 0.6

mg/L < 5.0

> Please note change. Source: Roche IFU.

INTERPRETATION:

- CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
- C-reactive protein is the classic acute phase protein in inflammatory reactions.
- CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis).
- CRP response may be less pronounced in patients suffering from liver disease.
- CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection."

----- End Of Report -----

DR. ADLEY MARK FERNANDES

M.D (Pathology) **Pathologist**

DR. VYOMA SHAH M.D (Pathology) **Clinical Pathologist**

agena V. Shah

ACCREDITED


Printed on:

ELOISA MAY DELMO

Laboratory Technologist

192 - LBPMBe 2 of 2

08-Aug-2025 03:19 PM



Test marked with # is performed in an accredited referral laboratory.